Poppi, a Texas-based beverage company that rose to prominence by marketing its sparkling prebiotic sodas as a gut-healthy alternative to traditional soft drinks, has become the subject of a high-profile national class action lawsuit that could reshape how functional beverages are advertised in the United States. The litigation, filed in California in May 2024, accused the company of misleading consumers with claims that its drinks provided meaningful digestive health benefits. Although Poppi denies wrongdoing, the company has agreed to an $8.9 million settlement, which is now awaiting final court approval.
The lawsuit was brought by a California consumer, who argued that Poppi’s marketing overemphasized digestive health benefits that could not reasonably be achieved by consuming its products as instructed. At the center of the complaint is Poppi’s use of prebiotic fiber derived from agave inulin. Each can of Poppi contains roughly two grams of this fiber, which plaintiffs claim is far below the amount needed to provide meaningful effects on gut microbiota or digestion. According to the filing, marketing materials that positioned Poppi as a “gut-healthy” choice left consumers with the impression that a single serving could make a significant impact, when in reality, meaningful results would require a far higher daily intake.
Critics also highlighted that drinking enough cans to approach a beneficial level of prebiotics would simultaneously increase sugar intake, which could undermine the very health claims being promoted. By creating this apparent contradiction, the lawsuit alleged that the company engaged in false and misleading advertising, violating consumer protection and false advertising statutes in California.
For its part, Poppi has consistently rejected the allegations. Company representatives maintain that the sodas are positioned as a healthier alternative to mainstream soft drinks, pointing to their lower sugar content, use of natural sweeteners, and inclusion of prebiotic fiber. Poppi has emphasized that its settlement is not an admission of liability but a practical resolution intended to avoid protracted legal costs and uncertainty.
The terms of the settlement cover a broad swath of consumers. Anyone in the United States who purchased any flavor or package size of Poppi between January 23, 2020, and July 18, 2025, is eligible to submit a claim. Depending on proof of purchase, consumers may recover varying amounts. Those with receipts or other documentation can claim reimbursement based on the size and quantity of packages purchased, while those without proof are eligible for a capped amount per household. The structure ensures that even occasional purchasers may be entitled to some compensation, with minimum payments guaranteed.
The deadline for filing claims has been set for September 26, 2025. A fairness hearing is scheduled for November 20, 2025, at which a judge will determine whether the settlement adequately serves the interests of the affected class. If approved, payouts would likely be distributed in 2026.
The lawsuit against Poppi reflects a broader tension in the fast-growing functional beverage industry. In recent years, consumer demand for drinks that promise more than hydration has soared, with companies touting everything from probiotics and prebiotics to adaptogens and antioxidants. Yet, as popularity has surged, so has scrutiny. Regulatory agencies, health professionals, and now the courts are increasingly challenging whether the claims made on labels match the scientific evidence supporting them.
For consumers, the Poppi case raises questions about what can reasonably be expected from products that occupy the gray space between traditional sodas and dietary supplements. While the inclusion of prebiotic fiber is not disputed, the matter of dosage and meaningful health outcomes remains unsettled. The settlement does not answer the underlying scientific question but does highlight how easily marketing language can shape perceptions about health benefits.
If finalized, the Poppi settlement may serve as a cautionary tale to other beverage companies eager to promote functional claims without substantial clinical backing. It may also prompt more stringent oversight from regulators and greater diligence from consumers navigating store shelves filled with promises of better health in a can.
At a time when Americans are more health-conscious than ever, the case illustrates the delicate balance between innovation, marketing, and accountability in the beverage sector. Poppi’s popularity is unlikely to vanish overnight, but the company’s legal journey underscores the growing demand for transparency and evidence in claims that touch directly on public health.